1 Min Read
Dec 5 (Reuters) - Resverlogix Corp :
* Press release - Resverlogix announces second positive recommendation from Data Safety Monitoring Board for Phase 3 study of Apabetalone (RVX-208)
* Data and Safety Monitoring Board reviewed available study data and noted that no safety or efficacy concerns were identified
* "First patients in trial have now surpassed one year mark and Apabetalone remains well-tolerated with a consistent safety profile."
* Data and Safety Monitoring Board for Co's Phase 3 BETonMACE trial recommended that study to continue as planned without any modifications Source text for Eikon: Further company coverage: